Yield10 Bioscience Announces First Quarter 2017 Financial Results

Woburn, Massachusetts, UNITED STATES

WOBURN, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) today reported financial results for the three months ended March 31, 2017.

Yield10 Bioscience kicked off the year with new branding, reflecting the mission to target the critical unmet need in agriculture based on the anticipated “yield gap” between agricultural supply and the growing global population. The Company's strategy is to leverage its track record in innovation and metabolic engineering in living systems to discover and develop novel yield trait genes that can be deployed in commercial crops to produce step-changes in yield.

The Company is executing a research and development plan for 2017 aimed at generating a range of important proof points in key crops.  For example, in the second quarter, Yield10 will begin the 2017 field testing program to evaluate its second generation (or improved) version of the C3003 yield trait genes in Camelina. In this field test, first generation C3003 will also be evaluated for the first time in canola under field test conditions.

“We expect to report data from the study in the fourth quarter, which will represent another key milestone in the evaluation of this promising trait in oilseed crops,” commented Oliver Peoples, Ph.D., President and Chief Executive Officer. “We are also making progress introducing C3003 into soybean and we are on track to obtain initial data in this crop in late 2017 or early 2018. In addition, we expect to have C3003 seed yield data from studies in rice in 2018.”

In 2017, Yield10 is also intensifying its efforts to evaluate genome editing targets for improving seed yield, seed composition and/or biomass yield in commercial crops.  The Company believes that strategies based on C3004, a trait that complements C3003, and on C3007, an oil content boosting trait that the Company has an option to in-license, have the potential to provide a path to commercialization based on achieving "unregulated" status from USDA-APHIS. If this status is achieved, this could significantly reduce the time and cost of launching new yield traits. These traits also complement the work Yield10 is doing with C3003 in oilseed crops, adding to a robust portfolio of yield traits targeting oilseed crops.  In addition, Yield10 is advancing research with a number of genome editing targets from the C4000 series of traits, which could provide new strategies to increase biomass yield in forage and other crops.

“In addition to generating a range of proof points, we also anticipate reaching corporate milestones in 2017, including forming collaborations, strengthening our balance sheet, capturing new sources of grant funding and filing for additional intellectual property around our crop science discoveries,” said Dr. Peoples.


Yield10 Bioscience is managed with an emphasis on cash flow and deploys its financial resources in a disciplined manner to achieve its key strategic objectives. The Company ended the first quarter with $4.9 million in unrestricted cash and cash equivalents. The Company’s net cash used in operating activities during the three months ended March 31, 2017 was $2.4 million, which was a decrease of $4.1 million from the $6.5 million used for operating activities during the three months ended March 31, 2016.  The decrease in cash usage is primarily the result of the Company’s lower net loss after discontinued operations of $2.1 million for the three months ended March 31, 2017, compared to a net loss of $6.5 million for the three months ended March 31, 2016.  The $4.4 million improvement is primarily due to a reduction in operating expenses associated with the Company's strategic restructuring, including a significant reduction in its full-time workforce.

The Company anticipates that it will need approximately $7.5 to $8.0 million of cash during 2017, including anticipated payments for remaining restructuring costs.  The Company’s present capital resources are not sufficient to fund its planned operations for a twelve month period and, therefore, raise substantial doubt about the Company’s ability to continue as a going concern.  The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing, including public or private equity financing, secured or unsecured debt financing, receipt of additional government research grants as well as licensing or other collaborative arrangements.

Continuing Operations

For the three months ending March 31, 2017, the Company reported a net loss from continuing operations of $2.1 million, or $0.07 per share, as compared to net loss from continuing operations of $3.5 million, or $0.13 per share, for the three months ended March 31, 2016.

Total research grant revenue for the three months ended March 31, 2017 was $0.3 million, compared to $0.2 million recorded for the three months ended March 31, 2016.  Research and development expenses and general and administrative expense from continuing operations were $1.1 million and $1.3 million, respectively, for the three months ended March 31, 2017 compared to $1.4 million and $2.3 million for the three months ended March 31, 2016.

Discontinued Operations

In July 2016, the Board of Directors of the Company approved a strategic restructuring plan under which Yield10 Bioscience became the Company's core business. As a result of this strategic shift, the Company completed the sale of its biopolymer assets in September 2016 in a transaction that met the requirements for discontinued operations reporting.  The Company's financial statements for the three months ended March 31, 2016 have therefore been prepared to reflect the Company's former biopolymer operations as a discontinued operation.  Net loss and net loss per share from discontinued operations were $3.0 million and $0.11, respectively, for the three months ended March 31, 2016.

Conference Call Information

Yield10 Bioscience management will host a conference call today at 4:30 p.m. (ET) to discuss first quarter results. The Company also will provide an update on the business and answer questions from the investor community. A live webcast of the call with slides can be accessed through the Company's website at www.yield10bio.com in the investor relations section. To participate in the call, dial toll-free 877-709-8150 or 201-689-8354 (international).

To listen to a telephonic replay of the conference call, dial toll-free 877-660-6853 or 201-612-7415 (international) and enter pass code 13658898. The replay will be available for 14 days. In addition, the webcast will be archived on the Company's website in the investor relations section.

About Yield10 Bioscience

Yield10 Bioscience, Inc. is focused on developing new technologies for producing step-change improvements in crop yield to enhance global food security.  Yield10 is leveraging an extensive track record of innovation based around optimizing the flow of carbon intermediates in living systems. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and corn.  Yield10 is based in Woburn, MA.

For more information visit www.yield10bio.com 

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, expectations regarding Yield10’s research and development activities, collaborations, intellectual property and value creation as well as the Company’s restructuring costs, cash position, cash forecasts, ability to obtain sufficient financing to continue operating, headcount forecasts, the reproducibility of data from field tests, the translation of yield improvements from Camelina to other crops, the potential to produce improvements in seed and/or biomass yield, the timing of completion of additional greenhouse and field test studies and receipt of data from those studies, and progress of Yield10 Bioscience, Inc., constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience’s filings with the Securities and Exchange Commission. Yield10 Bioscience assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


(In thousands, except share and per share amounts)
  Three Months Ended March 31,
  2017 2016
Grant revenue $324  $157 
Total revenue 324  157 
Research and development 1,109  1,428 
General and administrative 1,276  2,272 
Total expenses 2,385  3,700 
Loss from continuing operations (2,061) (3,543)
Other (expense) income, net (31) 3 
Net loss from continuing operations (2,092) (3,540)
Discontinued operations:    
Loss from discontinued operations   (2,958)
Total loss from discontinued operations   (2,958)
Net loss $(2,092) $(6,498)
Basic and Diluted net loss per share:    
Net loss from continuing operations $(0.07) $(0.13)
Net loss from discontinued operations   (0.11)
Net loss per share $(0.07) $(0.24)
Number of shares used in per share calculations:    
Basic & Diluted 28,399,811  27,367,305 

(In thousands, except share and per share amounts)
 March 31,
 December 31,
Current Assets:   
Cash and cash equivalents$4,875  $7,309 
Accounts receivable210  66 
Due from related parties  1 
Unbilled receivables114  121 
Prepaid expenses and other current assets460  363 
Total current assets5,659  7,860 
Restricted cash432  432 
Property and equipment, net1,686  1,739 
Deferred equity financing costs622  622 
Other assets95  95 
Total assets$8,494  $10,748 
Liabilities and Stockholders' Equity   
Current Liabilities:   
Accounts payable$51  $56 
Accrued expenses2,536  2,702 
Total current liabilities2,587  2,758 
Lease incentive obligation, net of current portion1,100  1,132 
Contract termination obligation, net of current portion246  489 
Total liabilities3,933  4,379 
Commitments and contingencies   
Stockholders' Equity:   
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding   
Common stock ($0.01 par value per share); 250,000,000 shares authorized at March 31, 2017 and December 31, 2016;
28,402,471 and 28,342,625 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively
284  283 
Additional paid-in capital339,811  339,527 
Accumulated other comprehensive loss(85) (84)
Accumulated deficit(335,449) (333,357)
Total stockholders' equity4,561  6,369 
Total liabilities and stockholders' equity$8,494  $10,748 

(In thousands)
  Three Months Ended March 31,
  2017 2016
Cash flows from operating activities    
Net loss $(2,092) $(6,498)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation 53  122 
Charge for 401(k) company common stock match 23  155 
Stock-based compensation 264  591 
Changes in operating assets and liabilities:    
Accounts receivable (144) (34)
Due from related parties 1  (58)
Unbilled receivables 7  97 
Inventory   (41)
Prepaid expenses and other assets (97) 280 
Accounts payable (5) 71 
Accrued expenses (168) (1,051)
Contract termination obligation and other long-term liabilities (275) (150)
Deferred revenue   (10)
Net cash used in operating activities (2,433) (6,526)
Cash flows from investing activities    
Purchase of property and equipment   (161)
Change in restricted cash   (307)
Net cash used by investing activities   (468)
Effect of exchange rate changes on cash and cash equivalents (1) (4)
Net decrease in cash and cash equivalents (2,434) (6,998)
Cash and cash equivalents at beginning of period 7,309  12,269 
Cash and cash equivalents at end of period $4,875  $5,271 
Supplemental disclosure of non-cash information:    
Purchase of property and equipment included in accounts payable and accrued expenses $  $476